Drug
Gilteritinib
Gilteritinib: highest development phase Phase 3, developed by Astellas. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Astellas
Trials
| Drug | Phase | Indication |
|---|---|---|
| gilteritinib NCT02997202 | Phase 3 | Acute Myeloid Leukemia |
| Gilteritinib NCT03836209 | Phase 2 | Acute Myeloid Leukemia |
Latest
No recent events.
Follow Gilteritinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.